A subsequent randomized clinical trial for patritumab plus erlotinib was terminated at an interim analysis because the patritumab arm did not show any clinical benefit compared to the placebo arm, in patients with locally advanced or metastatic NSCLC with high heregulin expression [36]. This evidence concerns the gene NRG1 and non-small cell lung carcinoma.